<div id="content" class="col-md-12" style="">
<div data-drupal-messages-fallback="" class="hidden"/><div id="block-medsites-page-title" class="widget block">
<h1><span property="schema:name">Myeloproliferative Neoplasms</span>
</h1>
</div>
<div id="block-medsites-content" class="widget block">
<article data-history-node-id="2985" role="article" about="/commodorecompendium/myeloproliferative-neoplasms" typeof="schema:WebPage">
<div>
<div property="schema:text" class="field field--name-body field--type-text-with-summary field--label-hidden field__item"><div class="WordSection1">
<div style="border-bottom:solid windowtext 1.0pt; border-top:double windowtext 1.5pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
<p style="border:none; padding:0in"><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="font-family:Palatino">Myeloproliferative Neoplasms (MPNs)—Christina Snider</span></span></b></span></span></span></span></p>
</div>
<p><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Background</span></span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">MPNs = chronic myeloid disorders caused by abnormal proliferation of mature bone marrow cell lineages (granulocytes, erythrocytes, or megakaryocytes)</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">MPNs differ from myelodysplastic syndrome (MDS)—cells in MPNs are normally developed (i.e. not dysplastic)</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Four “classic” MPNs: polycythemia vera, essential thrombocythemia, primary myelofibrosis and chronic myeloid leukemia (CML)</span></span></span></span></span></span></span></li>
</ul>
<p> </p>
<div style="border-bottom:solid windowtext 1.0pt; border-top:solid windowtext 1.0pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
<p style="border:none; padding:0in"><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="font-family:Palatino">Polycythemia Vera (PV)</span></span></b></span></span></span></span></p>
</div>
<ul>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Polycythemia is a general term: Men = Hb/Hct &gt; 16.5/49%;  Women = Hb/Hct &gt; 16/48%</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Relative polycythemia</span></span></span></b><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black"> = Concentrated H/H due to<i> </i>decreased plasma volume</span></span></span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Diuretic use, vomiting, diarrhea;  H/H should normalize with fluid resuscitation </span></span></span></span></span></span></span></span></li>
</ul>
</li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Absolute polycythemia</span></span></span></b><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black"> = Increased RBC mass</span></span></span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Primary</span></span></span><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black"> polycythemia: 2/2 Inherited/acquired mutation in RBC progenitor</span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Secondary polycythemia: Increase in RBC mass due to elevated serum EPO</span></span></span></span></span></span></span></span>
<ul style="list-style-type:disc">
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Hypoxia/cardiopulmonary associated (chronic pulmonary disease, R-to-L cardiac shunts, sleep apnea, obesity hypoventilation syndrome, chronic carbon monoxide poisoning, including heavy smoking)</span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Kidney associated causes (following renal transplant, renal artery stenosis, hydronephrosis)</span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Autonomous EPO production from an EPO-producing tumors (rare)</span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Steroid Use</span></span></span></span></span></span></span></span></li>
</ul>
</li>
</ul>
</li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Epidemiology: Median age of diagnosis is 60 years; 25% cases present at age &lt;50 years.</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">&gt;95% PV pts have <i>JAK2</i> V617F mutation, but <i>JAK2 </i>V617F mutation is not specific to PV and can be seen in other MPNs</span></span></span></span></span></span></span></li>
</ul>
<p style="margin-left:24px"> </p>
<p><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Presentation</span></span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Incidentally elevated H/H </span></span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Splenomegaly, generalized pruritus (post-warm bath/shower), unusual thrombosis</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Erythromelalgia: intermittent occurrence of red, hot, painful extremities</span></span></span></span></span></span></span></li>
</ul>
</div>
<p> </p>
<div class="WordSection2">
<p><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Evaluation</span></span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">CBC with differential and peripheral smear</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">EPO level</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Rule out secondary causes: Sleep Study, Carboxyhemoglobin, steroids</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Peripheral blood screen for <i>JAK2</i> V617F mutation</span></span></span></span></span></span></span></li>
</ul>
<p> </p>
<p><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Management</span></span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">PV treatment aims to prevent thrombosis and bleeding events.  </span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Phlebotomy: maintain Hct &lt;45% (One unit 500 mL decreases Hct by 3%)</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">ASA 81 mg for thrombosis prevention and symptom control</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Hydroxyurea: indicated for high-risk patients (&gt;60 years old or with history of thrombosis)</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Interferon-alfa, busulfan, or ruxolitinib: indicated in select high-risk patients </span></span></span></span></span></span></span></li>
</ul>
<p style="margin-left:24px"> </p>
<div style="border-bottom:solid windowtext 1.0pt; border-top:solid windowtext 1.0pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
<p style="border:none; margin-bottom:11px; padding:0in"><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="font-family:Palatino">Essential thrombocythemia (ET)</span></span></b></span></span></span></span></p>
</div>
<p class="p1"><span style="page:WordSection2"><span style="font-size:6pt"><span style="font-family:&quot;Helvetica Neue&quot;"><span style="color:#404040"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Background</span></span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Clonal stem cell disorder w/ increased platelet counts (&gt;450k/uL) </span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Risks of thrombosis and hemorrhage</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Median age of diagnosis: 60 years; Twice as common in females.</span></span></span></span></span></span></span></li>
</ul>
<p> </p>
<p class="p1"><span style="page:WordSection2"><span style="font-size:6pt"><span style="font-family:&quot;Helvetica Neue&quot;"><span style="color:#404040"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Presentation</span></span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Incidental thrombocytosis on CBC</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Splenomegaly, unusual thrombosis, and erythromelalgia </span></span></span></span></span></span></span></li>
</ul>
<p class="p1"> </p>
<p class="p1"><span style="page:WordSection2"><span style="font-size:6pt"><span style="font-family:&quot;Helvetica Neue&quot;"><span style="color:#404040"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Evaluation</span></span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Screen for conditions that cause reactive thrombocytosis: Chronic inflammatory diseases, infections, bleeding/hemolysis, iron deficiency, post splenectomy</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">CBC with smear (platelet anisocytosis) ranging from very small to giant platelets</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">CMP, LDH, Uric Acid, iron studies </span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">BCR ABL1 testing may be sent to exclude CML</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Bone marrow biopsy with staining, cytogenetics, and molecular testing for JAK2 mutations</span></span></span></span></span></span></span></li>
</ul>
<p> </p>
<p><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Management</span></span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Avoid ASA 81 in patients with platelet counts &gt;1 million/uL microL complicated by acquired von Willebrand syndrome due to increased risk of bleeding</span></span></span></span></span></span></span></li>
</ul>
<p style="margin-left:48px"> </p>
<table class="TableGrid3" style="border-collapse:collapse; border:none" width="348">
<tbody>
<tr>
<td colspan="3" style="border-bottom:1px solid black; width:348px; padding:0in 7px 0in 7px; background-color:black; border-top:1px solid black; border-right:1px solid black; border-left:1px solid black" valign="top">
<p align="center" style="text-align:center"><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:white">Treatment of ET</span></span></span></b></span></span></span></span></p>
</td>
</tr>
<tr>
<td style="border-bottom:1px solid black; width:102px; padding:0in 7px 0in 7px; height:6px; background-color:black; border-top:none; border-right:1px solid black; border-left:1px solid black" valign="top">
<p align="center" style="text-align:center"><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:white">Risk Score</span></span></span></b></span></span></span></span></p>
<p align="center" style="text-align:center"><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:white">(</span></span></span></b><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:white">IPSET-thrombosis)</span></span></span></span></span></span></span></p>
</td>
<td style="border-bottom:1px solid black; width:144px; padding:0in 7px 0in 7px; height:6px; background-color:black; border-top:none; border-right:1px solid black; border-left:none" valign="top">
<p><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:white">Features</span></span></span></b></span></span></span></span></p>
</td>
<td style="border-bottom:1px solid black; width:102px; padding:0in 7px 0in 7px; height:6px; background-color:black; border-top:none; border-right:1px solid black; border-left:none" valign="top">
<p align="center" style="text-align:center"><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:white">Treatment</span></span></span></b></span></span></span></span></p>
</td>
</tr>
<tr>
<td style="border-bottom:1px solid black; width:102px; padding:0in 7px 0in 7px; background-color:#e7e6e6; border-top:none; border-right:1px solid black; border-left:1px solid black">
<p align="center" style="text-align:center"><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">High</span></span></span></b></span></span></span></span></p>
</td>
<td style="border-bottom:1px solid black; width:144px; padding:0in 7px 0in 7px; background-color:#e7e6e6; border-top:none; border-right:1px solid black; border-left:none" valign="top">
<p><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Hx of thrombosis and/or &gt;age 60 with JAK2 V617F mutation</span></span></span></span></span></span></span></p>
</td>
<td rowspan="2" style="border-bottom:1px solid black; width:102px; padding:0in 7px 0in 7px; background-color:#e7e6e6; border-top:none; border-right:1px solid black; border-left:none" valign="top">
<p><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Cytoreduction (target plt 100-400k) w/ hydroxyurea, systemic anticoagulation +/-antiplatelet agent</span></span></span></span></span></span></span></p>
</td>
</tr>
<tr>
<td style="border-bottom:1px solid black; width:102px; padding:0in 7px 0in 7px; height:28px; border-top:none; border-right:1px solid black; border-left:1px solid black">
<p align="center" style="text-align:center"><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Intermediate</span></span></span></b></span></span></span></span></p>
</td>
<td style="border-bottom:1px solid black; width:144px; padding:0in 7px 0in 7px; height:28px; border-top:none; border-right:1px solid black; border-left:none" valign="top">
<p><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Age &gt;60, no JAK2 V617F mutation, no history of thrombosis</span></span></span></span></span></span></span></p>
</td>
</tr>
<tr>
<td style="border-bottom:1px solid black; width:102px; padding:0in 7px 0in 7px; background-color:#e7e6e6; border-top:none; border-right:1px solid black; border-left:1px solid black">
<p align="center" style="text-align:center"><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Low</span></span></span></b></span></span></span></span></p>
</td>
<td style="border-bottom:1px solid black; width:144px; padding:0in 7px 0in 7px; background-color:#e7e6e6; border-top:none; border-right:1px solid black; border-left:none" valign="top">
<p><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Age =&lt;60 w/ JAK2 V617F mutation and no history of thrombosis</span></span></span></span></span></span></span></p>
</td>
<td rowspan="2" style="border-bottom:1px solid black; width:102px; padding:0in 7px 0in 7px; border-top:none; border-right:1px solid black; border-left:none" valign="top">
<p><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Observation vs. daily ASA 81</span></span></span></span></span></span></span></p>
<p> </p>
</td>
</tr>
<tr>
<td style="border-bottom:1px solid black; width:102px; padding:0in 7px 0in 7px; height:29px; border-top:none; border-right:1px solid black; border-left:1px solid black">
<p align="center" style="text-align:center"><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Very Low</span></span></span></b></span></span></span></span></p>
</td>
<td style="border-bottom:1px solid black; width:144px; padding:0in 7px 0in 7px; height:29px; border-top:none; border-right:1px solid black; border-left:none" valign="top">
<p><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Age =&lt;60, no JAK2 V617F mutation, no history of thrombosis</span></span></span></span></span></span></span></p>
</td>
</tr>
</tbody>
</table>
<p> </p>
</div>
<p> </p>
<div style="border-bottom:solid windowtext 1.0pt; border-top:solid windowtext 1.0pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
<p style="border:none; padding:0in"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="font-family:Palatino">Primary Myelofibrosis (PMF)</span></span></b></span></span></span></p>
</div>
<p><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Background</span></span></span></span></span></span></p>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Clonal proliferation of myeloid cells with variable morphologic maturity resulting in reactive marrow fibrosis and extramedullary hematopoiesis</span></span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Least favorable prognosis out of MPN</span></span></span></span></span></span></li>
</ul>
<p> </p>
<p><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Presentation</span></span></span></span></span></span></p>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Fatigue, weight loss, low grade fever, bone pain, and night sweats</span></span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Marked splenomegaly +/-hepatomegaly (due to extramedullary hematopoiesis)</span></span></span></span></span></span></li>
</ul>
<p> </p>
<p><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Evaluation</span></span></span></span></span></span></p>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">smear: teardrop shaped RBCs (dacrocytes)</span></span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Bone marrow biopsy: “dry tap” due to extensive reticulin and/or collagen fibrosis</span></span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">mutually exclusive mutations in<i> </i>JAK2, MPL, or CALR</span></span></span></span></span></span></li>
</ul>
<p> </p>
<p><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Management</span></span></span></span></span></span></p>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Low risk patients: Observe if asymptomatic</span></span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Cure by allogenic HCT transplantation in young, high risk patients</span></span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Complex treatment options, consult Hematology</span></span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Treatment of anemias include transfusion support </span></span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Surgical splenectomy if abdominal pain or transfusion dependent anemia</span></span></span></span></span></span></li>
</ul>
<p> </p>
<div style="border-bottom:solid windowtext 1.0pt; border-top:solid windowtext 1.0pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
<p style="border:none; padding:0in"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="font-family:Palatino">Chronic Myelogenous Leukemia (CML)</span></span></b></span></span></span></p>
</div>
<p><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Background</span></span></span></span></span></span></p>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Definition: MPN overproduction of myeloid stem cells that can differentiate</span></span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Chronic phase: 85% of pts</span></span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Fatigue, weight loss, bleeding</span></span></span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Abdominal fullness and early satiety due to splenomegaly</span></span></span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">WBC on CBC is typically &gt;100k, and smear shows neutrophilic cells in all stages of maturation with &lt;2% blasts</span></span></span></span></span></span></span></li>
</ul>
</li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Accelerated phase: Refractory leukocytosis, 10-19% blasts in peripheral blood or bone marrow, worsening peripheral basophilia, thrombocytopenia</span></span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Blast phase = acute leukemia. &gt;20% blasts in peripheral blood or bone marrow, extramedullary proliferation of blasts</span></span></span></span></span></span></li>
</ul>
<p> </p>
<p><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Evaluation</span></span></span></span></span></span></p>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Typical findings in blood and bone marrow and confirmation of Philadelphia chromosome (<i>BCR-ABL1</i> fusion gene) via conventional cytogenetics, FISH, or rt-PCR</span></span></span></span></span></span></li>
</ul>
<p> </p>
<p><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Management</span></span></span></span></span></span></p>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Hydroxyurea can be used to reduce WBC while awaiting confirmation</span></span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Oral tyrosine kinase inhibitors (TKIS): Imatinib, dasatinib, nilotinib, and ponatinib</span></span></span></span></span></span></li>
<li><span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:Palatino"><span style="color:black">Allogenic hematopoietic cell transplantation: Curative option for pts in accelerated and blast phase, as well as young pts w/chronic phase CML who do not respond to TKI therapy</span></span></span></span></li>
</ul>
</div>
</div>
</article>
</div>
</div>